A breakthrough triple therapy for advanced prostate cancer can give patients years more of healthy life and reduces the overall risk of death by a third.
According to The Daily Mail, the regime involves two standard therapies alongside a powerful new hormone medication, darolutamide. The new drug has already proved to be effective as a standalone treatment in the earlier stages of the disease, when given to men who have stopped responding to other medications.
But a pivotal trial has now shown that when combined with standard therapies, it also has a dramatic effect in patients whose cancer has spread throughout the body.
Although a cure isn't possible for these men, using darolutamide, chemotherapy and other hormone medicines reduced pain, slowed the progression of the disease and extended survival. The men on the trial were mostly in their late 60s, although one patient was 89.
Those given the new combination therapy went for four years before their cancer began to progress, while in patients given the standard treatments alone their cancer worsened after just six months.
Professor Alison Birtle, consultant clinical oncologist at Lancashire Teaching Hospitals NHS Foundation Trust, called the advance "exciting". She added: "We've never had the option of a triple therapy like this before."
This study provides a compelling argument to adding darolutamide to standard chemo and hormone treatment, as it will help men with advanced prostate cancer live longer, healthier lives, with less pain. There are roughly 52,000 new prostate cancer cases every year in the UK.
For those men with earlier-stage disease, surgery is typically offered to remove the prostate – and tumor within – in the hope of a cure.
If they reject surgery, which men often do as the procedure can lead to incontinence and erectile dysfunction, they are offered drugs to limit the amount of the male hormone testosterone they produce, which prostate cancers use to grow.
In 15,000 men a year the disease has already spread by the time they are diagnosed – and in many cases surgery is pointless. Instead, chemotherapy, radiotherapy and hormone drugs shrink tumors and keep the disease at bay for as long as possible. But in incurable cases, most patients eventually become resistant to standard hormone drugs.